In the courtroom testimony that has unfolded so far in the criminal trial of Theranos Inc. founder Elizabeth Holmes, jurors have heard about the early promise of her startup and how Ms. Holmes set out to revolutionize healthcare by eliminating big needles from blood testing.
They have also begun to hear about how the company’s ambitions to test for a range of conditions using just a few drops of blood from a finger prick fell short, and how some employees quit after they said they tried to sound the alarm that the company was allegedly putting patient health at risk. Witnesses and prosecutors have also described years that Theranos struggled to pay the bills, and how revenue projections given to investors were sometimes far rosier than what the company’s finance staff calculated.
